From: Bendamustine in patients with relapsed or refractory multiple myeloma
Subgroups therapy mode | Subgroups dosage | ||||||
---|---|---|---|---|---|---|---|
Total | Monotherapy | + Steroids | p | 80-100 mg/m 2 | 120-150 mg/m 2 | p | |
Age | 61 (41-83) | 61 (41-83) | 61 (47-68) | 0.4 | 63 (41-76) | 61 (42-83) | 0.7 |
Sex | |||||||
male | 15 (38%) | 8 (67%) | 16 (59%) | 0.7 | 13 (62%) | 11 (61%) | 1 |
female | 24 (62%) | 4 (33%) | 11 (41%) | 0.7 | 8 (38%) | 7 (39%) | 1 |
Myeloma subtype | |||||||
IgG | 35 (90%) | 11 (92%) | 24 (89%) | 1 | 20 (95%) | 15 (83%) | 0.3 |
Other | 4 (10%) | 1 (8%) | 3 (11%) | 1 | 1 (5%) | 3 (17%) | 0.3 |
ISS stage | |||||||
I | 16 (41%) | 1 (8%) | 15 (56%) | 0.01 | 9 (43%) | 7 (38%) | 1 |
II | 11 (28%) | 6 (50%) | 5 (19%) | 0.1 | 6 (29%) | 5 (28%) | 1 |
III | 7 (18%) | 3 (25%) | 4 (15%) | 0.7 | 4 (19%) | 3 (17%) | 1 |
Not available | 5 (13%) | 2 (17%) | 3 (11%) | 0.6 | 2 (9%) | 3 (17%) | 0.6 |
Salmon & Durie stage | |||||||
I | 2 (5%) | 2 (17%) | 0 (0%) | 0.1 | 1 (5%) | 1 (6%) | 1 |
II | 7 (18%) | 0 (0%) | 7 (26%) | 0.1 | 2 (10%) | 5 (28%) | 0.2 |
III | 30 (77%) | 10 (83%) | 20 (74%) | 0.7 | 18 (86%) | 12 (67%) | 0.3 |
Metaphase cytogenetics | |||||||
Normal | 26 (67%) | 8 (67%) | 18 (67%) | 1 | 15 (71%) | 11 (61%) | 0.5 |
Abnormal | 7 (18%) | 2 (17%) | 5 (19%) | 1 | 4 (19%) | 3 (17%) | 1 |
Not done | 6 (15%) | 2 (17%) | 4 (15%) | 1 | 2 (10%) | 4 (22%) | 0.4 |
Osteolytic lesions | 29 (84%) | 9 (75%) | 20 (74%) | 1 | 17 (81%) | 12 (67%) | 0.5 |
Extramed. Disease | 11 (28%) | 3 (25%) | 8 (30%) | 1 | 6 (29%) | 5 (28%) | 1 |
Previous Therapy | |||||||
Refractory disease | 22 (56%) | 7 (58%) | 15 (56%) | 1 | 11 (52%) | 11 (61%) | 0.8 |
Relapsed disease | 17 (44%) | 5 (42%) | 12 (44%) | 1 | 10 (48%) | 7 (38%) | 0.8 |
Prior lines of therapy | 2 (1-5) | 2 (1-5) | 2 (1-5) | 1 | 2 (1-5) | 2 (1-5) | 1 |
Prior radiotherapy | 27 (69%) | 9 (75%) | 18 (67%) | 0.7 | 15 (71%) | 12 (67%) | 1 |
Prior thalidomide | 23 (59%) | 5 (42%) | 18 (67%) | 0.2 | 11 (52%) | 12 (67%) | 0.5 |
Prior HDT | 25 (64%) | 5 (42%) | 20 (74%) | 0.1 | 11 (52%) | 14 (78%) | 0.2 |
Prior 2nd salvage HDT | 9 (23%) | 2 (17%) | 4 (15%) | 1 | 2 (10%) | 4 (22%) | 0.4 |
β2-microglobulin [mg/l] | 3.0 (1.3-8.4) | 4.8 (2.2-7.7) | 2.6 (1.3-8.4) | 0.2 | 2.7 (1.7-7.7) | 3.4 (1.3-8.4) | 0.9 |
LDH [U/l] | 178 (95-988) | 244 (137-536) | 174 (95-988) | 0.6 | 185 (114-613) | 172 (95-988) | 0.8 |
Calcium [mmol/l] | 2.6 (1.9-3.1) | 2.46 (2.1-2.5) | 2.3 (1.9-3.1) | 0.5 | 2.3 (2.0-2.5) | 2.6 (1.9-3.1) | 1.0 |
CRP [mg/l] | 0.8 (0.1-14.2) | 1 (0.1-3.1) | 0.8 (0.1-14.2) | 0.5 | 0.8 (0.1-11.3) | 0.8 (0.1-14.2) | 0.8 |
Haemoglobine level [g/l] | 11.5 (7.4-17.4) | 11.4 (7.9-14.4) | 12.2(7.4-17.4) | 0.3 | 11.6 (7.9-14.4) | 11.4 (7.4 - 14.3) | 0.8 |
Platelet counts [× 1.000/μl] | 148 (20-455) | 161 (20-319) | 140 (38-455) | 0.8 | 140 (20-319) | 168 (38-455) | 0.1 |
Creatinine [mg/ml] | 0,9 (0,4-5,2) | 1,2 (04,-5,2) | 0,9 (0,4-1,6) | 0,2 | 0,9 (0,4-1,5) | 1,0 (0,4-5,2) | 0,5 |